Search
This project aimed to identify the primordial determinants of RHD to inform prevention strategies.
We are conducting a genetic study to better understand why some people are susceptible to RHD and others are not.
The main objective of the study is to establish a comprehensive register of congenital and acquired heart disease in WA with accurate re-classification of all cases through Princess Margart Hospital using international diagnostic codes.
This project aims to develop a longer acting formulation of penicillin, such that frequency of the injection can be increased up to 3-6 months.
Aims: To determine the minimum inhibitory concentrations of penicillin G against a representative collection of Strep A strains; and to evaluate the impact of penicillin G concentration and size of bacterial inoculum on the prophylactic effect for Strep A strains
This project will use a multi-jurisdictional linked RHD dataset to establish a baseline burden of RHD in Australia to allow for monitoring the impact of burden over time, and to form the basis of clearly defined targets for the END RHD CRE Endgame Strategy.
The key objective of this study is to collect data about patient and clinician preferences about reformulations.
The goal of the program is to establish the foundations of an effective, sustainable and equitable response to RHD in the Pacific.
In this study we will use new methods to comprehensively test immune responses in blood samples from people with ARF (diagnosed using the Jones Criteria) and healthy volunteers at Royal Darwin and from Auckland Hospital, New Zealand, to find any unique signature that reliably identifies ARF.
The END RHD CRE will undertake a number of projects across several disciplines of research including epidemiology, biomedical sciences; implementation and translation; and understanding the RHD community with a special focus on documenting the experiences of those living with the disease.